ArticleGlobal health, epidemiology and genomics2026
Over Three Decades of Mental Health in Sub-Saharan Africa: An Analysis of GBD Data From 1990 to 2023.
Article in Global health, epidemiology and genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Over Three Decades of Mental Health in Sub-Saharan Africa: An Analysis of GBD Data From 1990 to 2023.Global health, epidemiology and genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMental disorders are leading causes of disability worldwide but remain underprioritized in many low- and middle-income countries, including sub-Saharan Africa (SSA), where access to care, workforce capacity, and mental health infrastructure remain limited.
objectiveThis study quantified the burden of mental and substance use disorders (SUDs) in SSA from 1990 to 2023 using Global Burden of Disease (GBD) 2023 estimates, with attention to long-term trends, late-period changes, country-level heterogeneity, sex differences, and risk-factor attribution.
methodsWe analyzed GBD 2023 estimates for 46 SSA countries from 1990 to 2023, including prevalence, disability-adjusted life years (DALYs), age-standardized rates, sex-specific estimates, country-level burden, and selected risk factors. Percentage changes were calculated for 1990-2023, with sensitivity analyses for 1990-2019 and 2019-2023 and segmented log-linear trend models using 2019 as the breakpoint.
resultsFrom 1990 to 2023, the age-standardized prevalence rate of mental disorders increased from 11,138.8 to 14,841.0 per 100,000 (+33.24%), while the age-standardized DALY rate increased from 1634.9 to 2218.9 per 100,000 (+35.73%). Anxiety disorders showed the largest relative increases in age-standardized prevalence (+90.99%) and DALY rates (+92.11%). Depressive disorders also increased, while ADHD age-standardized rates remained largely stable. SUDs showed rising absolute burden despite declining age-standardized prevalence and DALY rates. Late-period analyses showed larger increases after 2019, particularly for anxiety disorders. Females had higher age-standardized rates and larger relative increases for anxiety and depressive disorders, whereas males had higher rates of ADHD and SUDs. Among selected risk factors, sexual violence against children had the highest age-standardized attributable DALY rate in 2023, while bullying victimization and intimate partner violence showed the largest relative increases.
conclusionMental and SUDs represent a growing public health challenge in SSA. Strengthening mental health systems, integrating services into primary and general healthcare platforms, expanding SUD prevention and treatment, addressing violence-related risk factors, and reducing stigma are essential to improving mental health outcomes across the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.